ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Evonik Pulls Back IPO, Invests In R&D

by Alexander H. Tullo
October 3, 2011 | APPEARED IN VOLUME 89, ISSUE 40

Evonik Industries has once again shelved an initial public offering (IPO) of stock. In April, RAG Foundation, which owns about 75% of the firm, said that it was considering an IPO within the next 15 months and that it would make its final decision by the fall. RAG Chairman Wilhelm Bonse-Geuking now says “the uncertainty in the financial and capital markets is bad for the IPO.” Evonik put the brakes on an IPO in 2008 because of the financial crisis. Separately, Evonik has begun construction on two new research facilities in Essen, Germany, that will cost about $42 million combined. One center, specializing in “environmentally friendly” additives and binders for the coatings industry, will be completed by the end of 2012. The other will focus on cosmetic ingredients and open in 2013.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment